Clinical Trial Update: Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression [Phase 2]

View source ↗

Summary

A Phase II trial of RG2417 for bipolar depression has completed, according to the clinical trials update; no efficacy results are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• RG2417

Snippet

Sponsor: Repligen Corporation | Conditions: Bipolar Depression | Phase 2 | Status: COMPLETED